Biofrontera Revenue Jumps 15% in Q2

Biofrontera (BFRI) reported Q2 2025 GAAP revenue of $9.0 million, surpassing analyst expectations by 8.4% due to a 9.5% increase in Ameluz® sales volume and a 5% price increase. Despite top-line growth, the company posted a wider net loss per share of $(0.57), missing consensus estimates, primarily driven by a significant rise in legal expenses. Strategically, Biofrontera secured a crucial patent extension for Ameluz® through 2043 and restructured its licensing agreement, reducing future royalty rates, indicating long-term intellectual property and cost management improvements amidst ongoing profitability challenges.

Analysis

Biofrontera (NASDAQ:BFRI) presented a mixed financial picture in its Q2 2025 results, characterized by strong top-line growth offset by widening losses. The company reported GAAP revenue of $9.0 million, a 15.4% year-over-year increase and an 8.4% beat on analyst estimates, driven by solid commercial execution for its flagship product, Ameluz®. This growth was fueled by a 9.5% increase in sales volume and a 5% price hike, demonstrating healthy demand and pricing power. Strategically, Biofrontera achieved two significant long-term milestones: extending Ameluz®'s U.S. patent protection to 2043 and restructuring its licensor agreement to lower royalty rates, which immediately reduced cost of revenues by 41.8%. However, these positive developments were overshadowed by a significant earnings miss, with a net loss per share of $(0.57) compared to the $(0.42) consensus estimate. The loss was primarily driven by a substantial surge in SG&A expenses to $10.5 million, which included a $3.4 million increase in legal costs. While the company's cash position improved to $7.2 million, this was due to $11 million in new funding, and total liabilities rose to $24.8 million, highlighting continued reliance on external capital amid negative adjusted EBITDA of $(5.1) million.

Key Decisions for Investors

• Investors should weigh the significant long-term value created by the Ameluz® patent extension to 2043 and improved gross margins against the near-term pressure from a $(0.57) net loss per share driven by surging legal costs.
• It is critical to monitor upcoming clinical trial catalysts, particularly Phase 3 data for superficial basal cell carcinoma and label expansion studies, as positive results could significantly expand the product's addressable market and justify the current operating spend.
• Given the negative adjusted EBITDA and rising liabilities, investors should carefully track the company's cash burn rate and any commentary on the path to profitability, as the potential need for future financing remains a key risk.